These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Correlation among hyperphosphatemia, type II sodium phosphate transporter activity, and vitamin D metabolism in Fgf-23 null mice. Sitara D Ann N Y Acad Sci; 2007 Nov; 1116():485-93. PubMed ID: 17646263 [TBL] [Abstract][Full Text] [Related]
35. Klotho Lacks an FGF23-Independent Role in Mineral Homeostasis. Andrukhova O; Bayer J; Schüler C; Zeitz U; Murali SK; Ada S; Alvarez-Pez JM; Smorodchenko A; Erben RG J Bone Miner Res; 2017 Oct; 32(10):2049-2061. PubMed ID: 28600880 [TBL] [Abstract][Full Text] [Related]
37. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia? Lee EK; Martinez MC; Blakely K; Santos KD; Hoang VC; Chow A; Emmenegger U Med Hypotheses; 2014 Oct; 83(4):482-7. PubMed ID: 25155552 [TBL] [Abstract][Full Text] [Related]
38. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. Nakai K; Komaba H; Fukagawa M J Nephrol; 2010; 23(6):619-25. PubMed ID: 20658451 [TBL] [Abstract][Full Text] [Related]
39. Bone mineralization is regulated by signaling cross talk between molecular factors of local and systemic origin: the role of fibroblast growth factor 23. Sapir-Koren R; Livshits G Biofactors; 2014; 40(6):555-68. PubMed ID: 25352227 [TBL] [Abstract][Full Text] [Related]
40. Vitamin D and type II sodium-dependent phosphate cotransporters. Kido S; Kaneko I; Tatsumi S; Segawa H; Miyamoto K Contrib Nephrol; 2013; 180():86-97. PubMed ID: 23652552 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]